Each 10-Gy increase in biologically effective dose was associated with 39% higher odds of pathological complete response in esophageal squamous cell carcinoma.
Internal mammary node boost was associated with better disease-free survival only when MRI showed residual nodal disease after neoadjuvant therapy.
Nearly 40% of visible internal mammary nodes regressed after chemotherapy, including 22% in patients without axillary nodal disease.
Total neoadjuvant therapy is now central to high-risk rectal cancer and organ preservation
Five-year overall survival was 78.1% with short-course total neoadjuvant therapy versus 69.7% with long-course chemoradiotherapy.
Concurrent neoadjuvant radiotherapy shortened treatment duration but did not improve pathological complete response or survival.
Induction chemotherapy showed no overall survival benefit, with outcomes differing by disease risk and the intensity of pre-radiotherapy treatment.